BI 1823911* is a highly potent and selective inhibitor targeting KRAS G12C mutations, which interferes with signalling, blocking proliferation, and causes tumor cell apoptosis.1
Clinical trials: BI 1823911 currently being investigated in a Phase I trial involving patients with advanced or metastatic solid tumours expressing the KRAS G12C mutation.2
KRAS functions as a molecular switch, intrinsically linked to and controlled by GTP-(‘on’) or GDP-(‘off’) binding. Its function is at the center of various signaling pathways, including the RAS-RAF-MEK-ERK cascade, which regulate several different processes including cell proliferation and survival.1
Mechanism of action
BI 1823911 selectively and covalently binds to G12C mutant KRAS, irreversibly locking it in its inactive GDP form, thereby interfering with signalling, blocking proliferation, and causing tumor cell apoptosis.1
Monotherapy with a KRAS G12C inhibitor may not be sufficient to achieve durable responses, whereas combination therapy may lead to enhanced anti-tumor efficacy and may address resistance mechanisms as well.3
Preclinical data identified strong synergistic anti-proliferative activity with BI 1701963, a pan-KRAS SOS1 inhibitor, and this combination will be tested in future studies.3,4
Initial data from in vivo and in vitro studies have shown that BI 1823911 showed promising anti-tumor responses against KRAS-dependent tumors, especially when given in combination with BI 1701963, a pan-KRAS SOS1 inhibitor.3 The combination showed increased and sustained pharmacodynamic modulation and deeper anti-tumor efficacy.3,4 A study is currently underway investigating the efficacy of BI 1823911 alone and in combination with BI 1701963 in advanced or metastatic cancers including lung cancer, colorectal cancer, pancreatic cancer, and bile duct cancer.2
|Trial number||Phase||Treatment||Patient population||Status|
A Phase I trial of BI 1823911 as monotherapy and in combination with BI 1701963 in patients with KRAS mutated advanced or metastatic solid tumors2
AE, adverse event; AUC, area under the curve; CR, complete response; CSS, steady state concentration; DLT, dose-limiting toxicity; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; KRAS, Kirsten rat sarcoma; MTD, maximum tolerated dose; OR, objective response; PFS, progression-free survival; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors.
BI 1823911 as monotherapy and in combination with BI 1701963
Advanced or metastatic solid tumors expressing KRAS G12C mutation
Explore our latest KRAS G12C inhibitor data
Our latest data on the KRAS G12C inhibitor was presented at the American Association for Cancer Research Congress 2021.
Boehringer Ingelheim, data on file.
ClinicalTrials.gov. NCT04973163. https://clinicaltrials.gov/ct2/show/NCT04973163 (Accessed: September 2021).
Savarese F et al. Poster presented at the American Association for Cancer Research Congress 2021.
Hofmann MH et al. Poster presented at the American Association for Cancer Research Congress 2021.
*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.
© 2021 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: September 2021
Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.
Do you want to continue ?Continue